Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q1 2026 · 10-Q
Revenue$32.00K$32.00K−98.5% vs Q1 2025 Net Income-$4.29M-$4.29MN/M vs Q1 2025 EPS Diluted-$0.12-$0.12N/M vs Q1 2025 Gross Profit$15,000−98.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flow-$7,639,000N/M Free Cash Flowderived-$8,252,000N/M Margins · derivedGross margin46.9%−15.1 pt vs Q1 2025
Operating margin-13790.6%−13472.6 pt vs Q1 2025
Net margin-13406.3%−13094.2 pt vs Q1 2025
ended Mar 31, 2026 · filed May 13, 2026 · 43 d after period end